Tiziana Life Sciences plc focuses on the discovery and development of molecules to treat human diseases in oncology,inflammation, and infectious diseases. Its lead product candidate in immunology is Foralumab (TZLS-401) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.
